| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | In conclusion, we found a suggestive beneficial association between higher MO3PUFA intake and improved survival among stage III colon cancer patients with wild-type KRAS and deficient MMR. | 30623420 | 2019 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. | 26160882 | 2015 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | The addition of cetuximab to FOLFOX4 did not improve DFS compared with FOLFOX4 alone in patients with KRAS exon 2 wild-type resected stage III colon cancer. | 24928083 | 2014 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | We evaluated the LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS) in patients with stage III colon cancer who enrolled in a phase III clinical trial (NCCTG N0147). | 24727325 | 2014 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | KRAS mutations in either codon 12 or 13 are associated with inferior survival in patients with resected stage III colon cancer. | 24687927 | 2014 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | We analyzed the prognostic impact of KRAS exon 2 mutations in stage III colon cancer patients (n = 1657) receiving adjuvant FOLFOX ± cetuximab therapy included in the PETACC8 trial. | 25294886 | 2014 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. | 19934290 | 2009 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | We determined the prognostic relevance of high-frequency MSI (MSI-H), TP53 mutations, and KRAS mutations in a well-defined group of patients with stage III colon cancer (N = 391), randomly assigned for adjuvant treatment with fluorouracil-based chemotherapy. | 16110022 | 2005 |